In GBM, we showed that ERRβsf is a transcriptionally active receptor that drives expression of p21, while ERRβ2 has no transcription factor activity and acts in a dominant-inhibitory fashion on the p21 promoter [27]. This evidence concerns the gene CDKN1A and glioblastoma.